⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166055 | 0.83 | TP53BP1 (0.33) | — | |
| SCHEMBL13950557 | 0.82 | — | — | |
| SCHEMBL18365002 | 0.78 | — | — | |
| SCHEMBL8962267 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL22851543 | 0.74 | — | — | |
| SCHEMBL238451 | 0.73 | KDM4E (0.34) | — | |
| SCHEMBL18542165 | 0.73 | — | — | |
| SCHEMBL29329112 | 0.72 | — | — | |
| SCHEMBL22851519 | 0.72 | — | — | |
| SCHEMBL21166077 | 0.72 | TP53BP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |